Autopsy report · NCT01100190

A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures

“Change in business priorities.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 4 years before it stopped.
• 100 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Ethicon, Inc.

Sponsor type

Industry

Conditions

Ptosis of the Neck, Mid-face and/or Jowl

Interventions

NUVANCE Facial Rejuvenation System

Participants

100 (planned, not actual)

Sites

9

Countries

France, Germany, Israel, United Kingdom

Trials that died the same way

• MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
  “Change in business priority” (83% match in meaning)
• Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
  “Change in company priorities” (82% match in meaning)
• 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
  “Business priorities” (81% match in meaning)
• A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
  “Business objectives have changed.” (71% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.